This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Bacterial infections	Resolvin D1 (RvD1); RvD5	<p>A study in mice suggests RvD1 and RvD5 could be useful for treating bacterial infections. In a mouse model of bacterial infection, Rvd1 and Rvd5 each decreased bacterial titers and fever and increased survival compared with no treatment. Next steps could include testing RvD1 and RvD5 in other mouse models of bacterial infection.</p> <p>Resolvix Pharmaceuticals Inc. has resolvin analogs in preclinical development for inflammatory, pulmonary and cardiovascular diseases.</p> <p>SciBX 5(22); doi:10.1038/scibx.2012.576 Published online May 31, 2012</p>	Patent and licensing status undisclosed	<p>Chiang, N. <i>et al. Nature</i>; published online April 25, 2012; doi:10.1038/nature11042 Contact: Charles N. Serhan, Harvard Medical School, Boston, Mass. e-mail: cnserhan@zeus.bwh.harvard.edu</p>